ClinicalTrials.gg
RecruitingNCT07042126Updated Nov 18, 2025

Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of 611 and Matching placebo in Dermatitis, Atopic, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
86th of 190
180 · median 164
Started
2025
with 33 others
Phase 3
60 of 206
21 open now
Primary completion
2026-06
later than 23 of 81 live
Registered
150th of 206
by date
Lead sponsor
8 of 206
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 86th largest by planned enrollment of the 190 interventional ones that give a count, is one of 34 that started in 2025, is one of 60 in phase 3, reaches primary completion later than 23 of the 81 other live ones, and was the 150th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

The primary objective of the study was to evaluate the efficacy of 611 in Chinese Adolescents with moderate to severe atopic dermatitis.

Read the detailed description

The maximum study duration was 64 weeks per participants, including a screening period of up to 4 weeks, a 16-week Double blind treatment period,a 36-week maintenance treatment period ,and an 8-week follow-up period.

03

Conditions studied

  • Dermatitis, Atopic

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects and their legal guardians are able to understand and comply with the research procedures, agree to participate in the research, and sign the Form (ICF).
  • When signing the informed consent form, the age should be ≥ 12 years old and \< 18 years old, gender is not restricted, and the body weight should be ≥ 30 kg at the screening and baseline.
  • During the screening process, patients were diagnosed with atopic dermatitis (AD) according to the Hanifin - Rajka criteria, and their AD medical history was evaluated by researchers to be ≥ 6 months (the diagnostic criteria are not restricted for the medical history).
  • At the screening and baseline, the Eczema Area and Severity Index (EASI) score is ≥ 16 points.
  • At the screening and baseline, the Investigator Global Assessment (IGA) score is ≥3 points.
  • At the time of screening and baseline, the affected body surface area (BSA) by atopic dermatitis (AD) is ≥10%.
  • At baseline, the weekly average score of the Numerical Rating Scale (NRS) for pruritus was ≥ 4 points.
  • Subjects should have relevant medical records, other medical visit records, or other evidence within the previous year for researchers to evaluate. The subjects have poor efficacy of topical drug treatment, or are medically unsuitable for topical drug treatment.
  • Be willing to use a stable dose of emollient (moisturizer) on the affected areas of atopic dermatitis (AD) twice a day for at least 7 days before randomization and continue to use it throughout the study period.
  • Subjects with potential fertility (e.g., females who have experienced menarche or males who have had nocturnal emissions) must agree to avoid sexual activity or use highly effective methods throughout the entire study period and for at least 3 months after the last dose of the medication.Subjects should have no plans for reproduction, sperm donation, or egg donation during the entire study period and for at least 3 months after the last dose of the medication.

Be able to understand and complete (either independently or with the assistance of a guardian) the research - related questionnaire filling.

Exclusion criteria

Exclusion Criteria:

  • Merge other skin comorbidities that may interfere with the research evaluation.
  • Combined with active parasitic infections (such as helminths) or suspected parasitic infections (subjects who have excluded active infections through clinical and/or laboratory examinations before randomization can be enrolled).
  • Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
  • Randomly select patients with any malignant tumor diagnosed within the past 5 years or currently having the disease (excluding basal cell carcinoma that has been cured for ≥ 1 year, local cutaneous squamous cell carcinoma, or carcinoma in situ of the cervix).
  • The subject had a severe infection requiring intravenous antibiotics and/or hospitalization within 4 weeks before randomization, or had an active infection requiring oral antibiotics within 2 weeks before randomization, and the investigator evaluated that there might be uncontrollable risks for the subject to participate in this study.
  • A history of known or suspected , including a history of invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis); or those who, although the infection has resolved, are considered by the investigator to be likely to have frequent recurrences.
  • Those with evidence of active tuberculosis, or those who have had active tuberculosis in the past but cannot provide sufficient evidence of treatment, or those who are judged to potentially have active tuberculosis infection based on examinations such as chest X - ray or CT, medical history, contact history, symptoms, and physical signs.
  • The researchers believe that there are any diseases that are severe or unstable and may affect the safety of the subjects during the study and/or prevent the subjects from completing the study, including but not limited to cardiovascular, gastrointestinal, liver, kidney, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, and mental diseases.
  • Currently receiving or having received the following treatments:

    1. Within the first 2 weeks randomly selected, patients have received topical drug treatment for atopic dermatitis (AD), such as TCS, TCI, PDE inhibitors, Janus kinase (JAK) inhibitors, etc.
    2. Within the first 4 weeks before randomization, the patients received systemic treatment with traditional Chinese medicine (TCM) of unknown nature or with therapeutic effects on AD. Or within the first 1 week before randomization, they received topical treatment with Chinese herbal medicine of unknown nature or with therapeutic effects on AD.
    3. Received systemic or other immunosuppressants/immunomodulators (including but not limited to cyclosporine, mycophenolate mofetil, interferon γ [IFN-γ], JAK inhibitors, compound glycyrrhizin, azathioprine, mycophenolate mofetil, and methotrexate) randomly within the first 4 weeks or 5 half - lives (whichever is longer).
    4. Received phototherapy (including but not limited to narrow - band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen plus ultraviolet A [PUVA]), tanning beds, or any other light - emitting devices with therapeutic effects on atopic dermatitis (AD) within the first 4 weeks randomly.
    5. Randomly selected patients who had received allergen-specific immunotherapy (SIT) within the previous 6 months.
    6. Received any monoclonal antibody therapy (such as dupilumab, etc.) within the first 4 months randomly or within 5 half-lives (whichever is longer) before randomization; Received any cell - depleting agents, including but not limited to rituximab, within 6 months before randomization.
    7. As judged by the researchers, patients had no response or poor efficacy to previous treatment with anti-IL-4 and/or IL-13 drugs (such as dupilumab, etc.).
    8. Previously, 611 was used.
    9. Treatment of atopic dermatitis (AD) with prescription emollients or emollients containing additives is initiated during the screening period.
  • Received or live attenuated vaccines within the first 4 weeks before randomization.
  • If any of the examination indicators before screening or randomization meet the following criteria and are judged by the researcher as unsuitable for inclusion in the study:≥1.5 ;/AST ≥2 ULN;Cr>1.5 ULN; blood WBC is lower than LLN, which is judged by the researcher to be and makes the subject ineligible for the study.
  • At the screening, the test results are positive for , positive for virus antibody (HCVAb), positive for antibody (HIVAb), and positive for serum Treponema pallidum antibody (TPAb).
  • Used any drugs within the first 8 weeks after randomization or 5 half-lives (whichever is longer);
  • Had a history of alcohol or drug abuse within 6 months before randomization;
  • Known to be allergic or intolerant to any components of the investigational drug;
  • Planned or were expected to undergo major surgical operations during the study period;
  • Pregnant women, women planning to become pregnant during the study period, or breastfeeding women;
  • According to the investigator's judgment, the subjects were not suitable to participate in the study due to other diseases or reasons.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    611

    Drug: 611

  • Placebo comparator
    placebo

    Drug: Matching placebo

Interventions

  • Drug611

    Double blind treatment period : 611 600 mg/450 mg at day 1,then 300 mg subcutaneous injection Q2W thereafter until week 16 Maintenance treatment period : 611 300 mg subcutaneous injection Q2W/Q3W until week 52.(The subjects in the placebo group during the double-blind treatment period need to be given a loading dose at week 16.)

  • DrugMatching placebo

    Double blind treatment period : placebo subcutaneous injection Q2W until week 16.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Improvement in Score From Baseline) at Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD

    Time frame: Baseline, Week 16

  2. Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Improvement From Baseline of Greater Than or Equal to (>=) 2 Points From Baseline to Week 16

    The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Improvement in Score From Baseline) at each efficacy evaluation visit point except for Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD

    Time frame: Baseline, Week 60

  2. Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Improvement From Baseline of Greater Than or Equal to (>=) 2 Points From Baseline to each efficacy evaluation visit point except for Week 16

    The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 60

  3. Number of Participants With EASI-50 (>=50% Improvement From Baseline)

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Baseline to Week 60

  4. Number of Participants With EASI-90 (>=90% Improvement From Baseline)

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD

    Time frame: Baseline, Week 60

  5. Number of Participants Who Achieved >=4 Points/ >=3 Points With Improvement From Baseline in Weekly Average of Pruritus Numerical Rating Scale (NRS) Score From Baseline

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline, Week 60

Other outcomes

  1. Adverse events (AEs), measurement of vital signs,physical examination,electrocardiogram and laboratory tests at each visit

    The incidence and severity of treatment emergent adverse event (TEAE), including Serious Adverse Event (SAE), as well as clinical symptoms, and any abnormalities of vital signs, physical examinations,electrocardiogram,laboratory tests and, etc.

    Time frame: Up to 60 Weeks

  2. Minimum concentration (Cmin)

    Minimum concentration (Cmin) of 611

    Time frame: Baseline to Week 60

  3. Percentage of Participants With Anti-drug Antibodies and Neutralizing Antibodies

    Immunogenicity assessment will be based on Anti-drug Antibodies (ADAs) response and development of Neutralizing Antibodies (NABs). Percentage is calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-drug antibodies / number of evaluable participants \* 100%

    Time frame: Baseline to Week 60.

07

Study locations

3 of 3 sites recruiting
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
    Recruiting
    • Jianzhong Zhang, Doctor · Contactrmzjz@126.com · 010-88325472
    • Jianzhong Zhang · Principal investigator
    • Yan Zhao · Sub investigator
  • The Fourth Affiliated Hospital Zhejiang University School of Medicine
    Jinhua, Zhejiang 322000, China
    Recruiting
  • Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
    Nanchang, Zhejiang 310003, China
    Recruiting
    • Liming Wu, Doctor · Contact18957118053@163.com · 13750837205
    • Liming Wu · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 10 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 27, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Sep 30, 2027
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07042126
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Aug 5, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 18, 2025

Study contacts

Qinghong Zhou, Master
Contact
zhouqinghong@3sbio.com
+86 18911301578

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camtarkibart

Start the discussion